Table 1 Baseline and follow-up characteristics of patients enrolled onto ART
Variable | BMI < 18.5 (N = 149) | BMI (18.5–24.99) (N = 530) | BMI (25–29.99) (N = 177) | BMI (≥30) (N = 92) | P-value |
|---|---|---|---|---|---|
Baseline | |||||
Median (IQR), age (years)a | 33 (29–39) | 33.5 (29–40) | 35 (28–42) | 36 (30–43) | 0.278 |
Female, %(n)b | 36.9 (55) | 49.6 (263) | 83.1 (147) | 90.1 (82) | < 0.001 |
WHO stage 1–3,% (n)c | 69.8 (104) | 84.9 (450) | 84.8 (150) | 93.4 (85) | < 0.001 |
WHO stage 4, % (n)c | 30.2 (45) | 15.1 (80) | 15.3 (27) | 6.6 (6) | |
CD4+, Median (IQR)d (cells /mm3) | 96 (35–187) | 132 (66–196) | 150 (75–224) | 140 (81–214) | 0.002 |
Mean (SD) viral load (log copies/ml)e | 5.2 (0.9) | 5.0 (0.8) | 4.7 (0.9) | 4.5 (1.0) | < 0.001 |
Tuberculosis at baseline | 55.7 (83) | 43.2 (229) | 32.8 (58) | 20.7 (19) | < 0.001 |
Follow-up | |||||
CD4+ increase > 50: baseline to 6 months, %(n) (N = 741) | 78.3 (83) | 80.4 (328) | 74.0 (111) | 70.1 (54) | 0.141 |
CD4+ increase > 50: baseline to 12 months, %(n) (N = 512) | 85.0 (68) | 85.7 (252) | 83.2 (79) | 83.7 (36) | 0.935 |
CD4+ increase > 50: baseline to 18 months, %(n) (N = 237) | 85.7 (24) | 91.4 (127) | 91.7 (44) | 86.4 (19) | 0.631 |
Undetectable viral load at 6 months, % (n) (N = 810) | 90.7 (107) | 93.7 (419) | 93.8 (152) | 92.7 (77) | 0.679 |
Undetectable viral load at 12 months, % (n) (N = 524) | 91.5 (75) | 95.0 (283) | 96.0 (96) | 90.9 (40) | 0.401 |
Undetectable viral load at 18 months, % (n) (N = 242) | 82.1 (23) | 93.0 (132) | 93.9 (46) | 87.0 (20) | 0.195 |